Fertility Preservation Considerations Before Hematologic Cancer Therapy

Abstract

Preserving fertility in patients with hematologic malignancies poised to undergo cytotoxic therapy is an increasingly pertinent concern in modern oncology and reproductive medicine. As survival rates improve due to advances in chemotherapeutic regimens and supportive care, long-term quality of life, including reproductive potential, has garnered significant attention. This review synthesizes current epidemiological data, elucidates mechanisms of gonadotoxicity, details risk stratification, and assesses evidence-based fertility preservation strategies. Emphasis is placed on integrating recent advances into clinical practice and aligning patient counseling with contemporary guideline recommendations.

Introduction

Hematologic cancers such as leukemia, lymphoma, and multiple myeloma often require aggressive therapies that jeopardize the fertility of patients in reproductive age groups. The imperative for fertility preservation is underscored by the shifting demographics of cancer survivorship and the evolving expectations for post-treatment quality of life. Clinicians must incorporate mechanisms of gonadal injury, individualized risk profiles, and the latest advances in fertility preservation into pre-treatment discussions to optimize patient care outcomes.

Epidemiology / Disease Burden

Hematologic malignancies account for a substantial proportion of cancer diagnoses in adolescents and young adults. According to recent data, approximately 10% of all new cancer cases in individuals aged 15–39 are hematologic in origin. Improvements in survival, particularly in childhood and adolescent leukemias and lymphomas, have led to a growing population of long-term survivors, many of whom face infertility as a critical late effect of therapy. The prevalence of treatment-induced infertility varies widely, with estimates ranging from 30% to over 80%, depending on age, gender, and treatment modality.

Pathophysiology

Cytotoxic therapies, especially alkylating agents (e.g., cyclophosphamide, busulfan) and total body irradiation, are highly gonadotoxic. In females, these interventions deplete the primordial follicle pool, resulting in premature ovarian insufficiency, while in males, they impair spermatogenesis by damaging the seminiferous tubules and Sertoli cells. The degree of gonadal injury is dose-dependent and influenced by patient age, with prepubertal tissues demonstrating differential sensitivities compared to postpubertal gonads. The underlying mechanisms involve direct DNA damage, oxidative stress, and microvascular compromise within the gonadal microenvironment.

Risk Factors

Risk stratification is essential for tailoring fertility preservation discussions. Key risk factors include high-dose alkylating agent exposure, hematopoietic stem cell transplantation (HSCT), pelvic or gonadal irradiation, and baseline gonadal reserve. Age at treatment initiation is a pivotal determinant; younger females possess a larger primordial follicle pool, while males exhibit variable testicular susceptibility based on pubertal stage. Genetic predispositions, such as BRCA mutations or underlying gonadal dysgenesis, may further modify risk.

Clinical Features

Clinical sequelae of gonadotoxic therapy manifest variably. Females may present with amenorrhea, menopausal symptoms, and infertility, whereas males frequently experience oligospermia, azoospermia, or hypogonadism. The latency between therapy and onset of reproductive dysfunction can range from months to years, and subclinical gonadal impairment may precede overt clinical symptoms. Monitoring hormonal markers (FSH, LH, estradiol, AMH in females; FSH, LH, testosterone, inhibin B in males) is essential for detecting early dysfunction.

Diagnosis

Assessment of fertility potential pre- and post-therapy involves clinical, hormonal, and imaging modalities. Ovarian reserve can be gauged via anti-Müllerian hormone (AMH) levels, antral follicle count (AFC), and baseline FSH. In males, semen analysis remains the gold standard, complemented by hormonal profiling. Testicular ultrasound may be indicated in select cases. Pre-treatment evaluation is critical for counseling and procedural planning, particularly when considering cryopreservation options.

Treatment & Management

Fertility preservation options must be discussed promptly at diagnosis, ideally before initiation of cytotoxic therapy. Established strategies include embryo and oocyte cryopreservation for females, and sperm cryopreservation for males. Ovarian tissue cryopreservation is emerging as a viable option, especially for prepubertal girls or when immediate therapy is required. Gonadal shielding during radiation and the use of gonadotropin-releasing hormone (GnRH) analogs in females are adjunctive measures, though the latter remains controversial in efficacy. Multidisciplinary collaboration among oncologists, reproductive endocrinologists, and counselors is vital for individualized management.

Recent Advances / Emerging Therapies

Technological and procedural innovations have expanded the armamentarium of fertility preservation. Vitrification has improved oocyte and embryo survival rates, while advances in testicular tissue cryopreservation and in vitro spermatogenesis offer future promise for prepubertal boys. Artificial ovary constructs and in vitro folliculogenesis are under investigation for restoring endocrine and reproductive function. Pharmacologic interventions aimed at mitigating gonadal injury, such as S1P analogs or antioxidants, are subjects of ongoing preclinical and clinical research.

Guideline Recommendations

International guidelines, including those from ASCO, ESMO, and ASRM, consistently recommend early fertility preservation counseling for all patients of reproductive age facing gonadotoxic therapy. Documentation of counseling, risk assessment, and referral to reproductive specialists is mandated. Embryo and oocyte cryopreservation are considered standard of care for females, while sperm banking is recommended for postpubertal males. Ovarian tissue cryopreservation is increasingly endorsed as non-experimental, particularly for pediatric patients. Patient-centered, multidisciplinary approaches are emphasized to align interventions with individual goals and clinical urgency.

Conclusion

Fertility preservation is an integral component of comprehensive hematologic cancer care, with profound implications for survivorship and quality of life. Timely risk assessment, utilization of evidence-based preservation strategies, and adherence to guideline recommendations are paramount. Ongoing research into novel techniques and protective agents holds promise for expanding reproductive options for cancer survivors. Effective communication and multidisciplinary collaboration remain the cornerstone of optimal patient outcomes in this rapidly evolving field.